Last reviewed · How we verify

Janssen Sciences Ireland UC — Portfolio Competitive Intelligence Brief

Janssen Sciences Ireland UC pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
FTC/TDF FDC FTC/TDF FDC phase 3 Nucleoside/nucleotide reverse transcriptase inhibitor combination HIV reverse transcriptase Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
  2. Brigham and Women's Hospital · 1 shared drug class
  3. Fundacion IDEAA · 1 shared drug class
  4. Merck Sharp & Dohme LLC · 1 shared drug class
  5. National Institute of Allergy and Infectious Diseases (NIAID) · 1 shared drug class
  6. University of Chicago · 1 shared drug class
  7. University of Washington · 1 shared drug class
  8. ViiV Healthcare · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen Sciences Ireland UC:

Cite this brief

Drug Landscape (2026). Janssen Sciences Ireland UC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-sciences-ireland-uc. Accessed 2026-06-10.

Related